Although there are multiple formulations of intravenous (IV) iron to choose from, a one-time
dose of Monoferric would make it more feasible to integrate it in the perioperative pathway
given an often-limited time between preoperative evaluation and surgery date. Furthermore,
the one-dose total iron repletion model can offer health economic benefits through reducing
red blood cell (RBC) transfusion applying limited resources to establish a perioperative
anemia management pathway. Prior studies have described a model that can be used as a
baseline which showed cost-savings and outlined each cost component. So far, no US-based
approach applying this model has been published.
Hypothesis: Administration of a one-time dose of IV iron to patients with preoperative iron
deficiency anemia scheduled to undergo elective abdominal and/or pelvic surgery is feasible.
It will result in an increase in preoperative hemoglobin from baseline, and improvement in
clinical outcomes.
Aim 1: Determine the change in hemoglobin from baseline after the administration of 1000mg
single dose IV iron 3-4 weeks before elective surgery The investigators hypothesize that
there will be an increase in hemoglobin levels by 1g/dL by the day of surgery.
Aim 2: Explore the association of IV iron administration on other clinical outcomes
including: complications, transfusion of blood products and length of hospital stay.
The investigators hypothesize that there will be a decrease in adverse complications and
requirement for transfusion, and shorter hospital stay
Aim 3: Describe the feasibility and process, infrastructure and workflows required to
implement an IV iron infusion program